Skip to Content

CASI Pharmaceuticals Inc CASI

Morningstar Rating
$3.50 +0.83 (31.09%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CASI is trading at a 886% premium.
Price
$2.69
Fair Value
$8.19
Uncertainty
Extreme
1-Star Price
$27.29
5-Star Price
$4.70
Economic Moat
Mwvvn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CASI is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.67
Day Range
$2.733.52
52-Week Range
$1.908.48
Bid/Ask
$3.46 / $3.50
Market Cap
$46.90 Mil
Volume/Avg
72,260 / 31,606

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.23
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.59%

Company Profile

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
243

Competitors

Valuation

Metric
CASI
PFE
Price/Earnings (Normalized)
19.13
Price/Book Value
2.311.68
Price/Sales
1.232.81
Price/Cash Flow
18.04
Price/Earnings
CASI
PFE

Financial Strength

Metric
CASI
PFE
Quick Ratio
3.010.67
Current Ratio
5.051.05
Interest Coverage
−0.26
Quick Ratio
CASI
PFE

Profitability

Metric
CASI
PFE
Return on Assets (Normalized)
−36.58%3.77%
Return on Equity (Normalized)
−97.49%8.51%
Return on Invested Capital (Normalized)
−56.29%5.75%
Return on Assets
CASI
PFE
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
SxzhdhfmfCtqg$631.1 Bil
Vertex Pharmaceuticals Inc
VRTX
BmscksgqJsyqpz$120.6 Bil
Regeneron Pharmaceuticals Inc
REGN
NqwfkkppPmqrv$114.5 Bil
Moderna Inc
MRNA
CczkxwwrhDrvz$51.1 Bil
argenx SE ADR
ARGX
MkdtbjrppYspy$22.6 Bil
BioNTech SE ADR
BNTX
SsksqgjrvBdf$20.8 Bil
Alnylam Pharmaceuticals Inc
ALNY
XcphysnlRsncp$19.5 Bil
Biomarin Pharmaceutical Inc
BMRN
WgnjdgnfvQwvnntl$16.0 Bil
United Therapeutics Corp
UTHR
ChnthzpxBsmh$13.6 Bil
Incyte Corp
INCY
HxnkxzwyWzvbqx$12.1 Bil

Sponsor Center